POST MEETING SURVEY – FDA-PDS SYMPOSIUM IX RARE CANCER REGISTRIES

What did you find most valuable at the FDA-PDS Symposium IX Rare Cancer Registries?

Learning more about PDS and its registry initiatives

Learning how my organization can use / better use registries

Learning about the latest research and initiatives on this key topic

Learning more about topics that are important to me professionally

Learning the perspective of FDA representatives on topics discussed

Which program segment did you find most interesting?

Keynote talk by Dr. Fajgenbaum

Panel 1: How do rare cancer registries impact clinical decision making?

Panel 2: How do rare cancer registries advance drugs in development?

Fireside Chat: Generating clinical evidence for biomarker-driven indications with Dr. Bilenker

How can we improve the content and/or the experience for our next event?

Leave this field blank

Search form